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Background: In vitro fabricated tissue engineered vascular constructs could provide an alternative to conventional
substitutes. A crucial factor for tissue engineering of vascular constructs is an appropriate cell source. Vascular cells
from the human umbilical cord can be directly isolated and cryopreserved until needed. Currently no cell bank for
human vascular cells is available. Therefore, the establishment of a future human vascular cell bank conforming to
good manufacturing practice (GMP) conditions is desirable for therapeutic applications such as tissue engineered
cardiovascular constructs.
Materials and methods: A fundamental step was the adaption of conventional research and development starting
materials to GMP compliant starting materials. Human umbilical cord artery derived cells (HUCAC) and human
umbilical vein endothelial cells (HUVEC) were isolated, cultivated, cryopreserved (short- and long-term) directly after
primary culture and recultivated subsequently. Cell viability, expression of cellular markers and proliferation potential
of fresh and cryopreserved cells were studied using trypan blue staining, flow cytometry analysis,
immunofluorescence staining and proliferation assays. Statistical analyses were performed using Student’s t-test.
Results: Sufficient numbers of isolated cells with acceptable viabilities and homogenous expression of cellular
markers confirmed that the isolation procedure was successful using GMP compliant starting materials. The
influence of cryopreservation was marginal, because cryopreserved cells mostly maintain phenotypic and functional
characteristics similar to those of fresh cells. Phenotypic studies revealed that fresh cultivated and cryopreserved
HUCAC were positive for alpha smooth muscle actin, CD90, CD105, CD73, CD29, CD44, CD166 and negative for
smoothelin. HUVEC expressed CD31, CD146, CD105 and CD144 but not alpha smooth muscle actin. Functional
analysis demonstrated acceptable viability and sufficient proliferation properties of cryopreserved HUCAC and
HUVEC.
Conclusion: Adaptation of cell isolation, cultivation and cryopreservation to GMP compliant starting materials was
successful. Cryopreservation did not influence cell properties with lasting impact, confirming that the application of
vascular cells from the human umbilical cord is feasible for cell banking. A specific cellular marker expression profile
was established for HUCAC and HUVEC using flow cytometry analysis, applicable as a GMP compliant quality
control. Use of these cells for the future fabrication of advanced therapy medicinal products GMP conditions are
required by the regulatory authority.
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Currently, cardiovascular diseases are the leading causes
of global death and disability. An estimated 17.3 million
people died from cardiovascular diseases in 2008 and
23.6 million people are predicted to die from them in
2030 [1]. Synthetic, metallic and biological grafts and
valves are frequently and successfully used as implants
in cardiac surgery, improving the quality of life for many
patients. However, lower compliance of synthetic materi-
als [2], higher thrombogenicity rates of metallic materi-
als [3] and limited durability of biological materials [4,5]
are undesirable limitations of these materials. Tissue
engineered cardiovascular constructs, consisting of auto-
logous cells that are incorporated in a biodegradable
hemodynamic scaffold, could be a promising alternative
to conventional replacements. Such constructs would be
able to integrate, to regenerate and to grow - an aspect
that is very attractive especially for pediatric patients
affected by congenital cardiac disease such as heart valve
failure [6]. Fabrication of functional implants requires
extracellular matrix (ECM) producing cells and additional
endothelial cells with antithrombogenic characteristics
[7]. Further, cellular structures and cell functionality
should be similar to those of native cardiovascular tissue,
ensuring successful integration into the surrounding
native tissue. Vascular cells from the human umbilical
cord vein and arteries, including endothelial cells,
smooth muscle cells and fibroblasts, represent a promis-
ing cell source for cardiovascular tissue engineering. Pre-
vious studies have shown that cells from the human
umbilical cord synthesize ECM proteins such as collagen
types I and III [8,9], also present in heart valves [10,11].
Kadner et al. found that umbilical cord artery derived
cells express cytoskeletal filament proteins such as alpha
smooth muscle actin (ASMA) and fibroblastic vimentin
and additionally show fibroblast like morphology. For
this reason they were considered to be myofibroblasts
[12], an intermediate cell type between fibroblast and
smooth muscle cells [13,14]. A comparative study
revealed that CD90, fibronectin and collagen type I
expression of human umbilical cord artery derived cells
is similar to that of pulmonary heart valve interstitial
cells. Furthermore, the expression of endothelial nitric
oxide synthase (eNOS) and von Willebrandt factor
(vWF) of endothelial cells from the human umbilical
cord vein (HUVEC) is similar to that of pulmonary heart
valve endothelial cells [15], showing that vascular cells
from the human umbilical cord resemble the native cel-
lular structures and functionalities found in heart valves.
These properties encouraged the application of vascular
umbilical cord cells for tissue engineering of cardiovascu-
lar constructs i.e. heart valves or blood vessels. Lüders
et al. first reported that fresh and cryopreserved cells iso-
lated from umbilical cord arteries and veins showedsimilar properties due to cell morphology and prolifera-
tion potential [16]. Continuative studies confirmed excel-
lent proliferation and ECM formation properties in vitro,
proving that cryopreserved vascular cells from the umbil-
ical cord are convenient for in vitro generation of func-
tional heart valves and for establishing autologous
human cell banks [17]. The human umbilical cord as a
potential source of vascular cells possesses several advan-
tages: after delivery, redundant cord tissue can be used
for direct isolation of the cells from cord vessels and no
additional surgical intervention is necessary for the
patient. Further, sufficient amounts of cells can be
obtained, because an ordinary human umbilical cord,
usually 20–22 in. long [18], provides enough tissue. Add-
itionally, isolated cells can be cryopreserved as needed
for operation. After cryopreservation cells can be thawed,
recultured and expanded for fabrication of cardiovascular
constructs. Using innovative cell banking technologies,
vascular cells from the human umbilical cord can be
used as an individual cell pool for the patient’s lifetime.
For this purpose, a cell bank providing high quality
vascular cells, produced by well controlled standardized
methods, represents an initial step for future fabrication
of cardiovascular constructs. Different types of cell
banks already exist worldwide. Amongst others, cells
and cell lines of animal or human origin are supplied by
the European Collection of Cell Cultures, established in
1984. The first successful umbilical cord blood trans-
plantation, performed by Elianne Gluckman in 1988 led
to the establishment of public cord blood banks world-
wide [19]. Today, more than 100 active cord blood
banks exist with more than 400,000 cord blood units
stored for unrelated use [20]. The UK Stem Cell Bank is
one of the most prominent non-profit stem cell banks,
storing human adult and fetal stem cell lines [21]. Cur-
rently, no public cell bank exists for storing human vas-
cular cells, even though the demand for primary cells in
cellular therapy has recently increased. Following rapid
development in the fields of biology, biotechnology and
medicine, and the development of innovative techniques
to examine diseases on the molecular and cellular level,
single genes and cells are applied to treat different dis-
eases. These so called “advanced therapy medicinal pro-
ducts” (ATMP) strongly differ from the medicinal
products for human use available so far. Therefore, the
new guideline “European Commission 1394/2007/EC”
was created to regulate the marketing authorization of
ATMP for innovative therapies [22]. ATMP comprise
somatic cell therapy medicinal products, gene therapy
medicinal products and tissue engineered medicinal pro-
ducts [23,24]. Concerning their first described future
medical application, vascular cells from umbilical cord
can be classified as ATMP which is of importance for
the establishment of a cell bank consisting of these cells.
Polchow et al. Journal of Translational Medicine 2012, 10:98 Page 3 of 17
http://www.translational-medicine.com/content/10/1/98Fabrication of cell-based medicinal products for clinical
trials should take place in compliance with the principles
of GMP, formulated in Commission Directive 2003/94/
EC [25]. Safety aspects represent one of the main con-
cerns in GMP production and refer to cell origin, the
choice of starting materials, the manufacturing process
itself and the associated quality controls [26]. Therefore,
the origin and fabrication process of all starting materials
should be adequately defined and well documented. The
use of animal derived reagents such as fetal calf serum
(FCS) should be avoided because of an increased risk of
undesirable immunological responses in the recipient
and a risk of the transmissible spongiform encephalop-
athy diseases. Furthermore, the fabrication process of the
cell-based product should be designed in depth and vali-
dated to ensure product reproducibility and efficiency.
To estimate the overall risk of a cell-based medicinal
product, the following criteria have to be followed: au-
tologous or allogenic origin, the ability of the cells to pro-
liferate and the level of cell manipulation, including
in vitro expansion, differentiation and cryopreservation.
In the recent study strategies for the establishment of a
human vascular cell bank corresponding to the GMP
guidelines were developed, to ensure essential quality and
identity of the desired final cell-based medicinal product.
The in vitro fabrication process for a cell bank was care-
fully designed by creating a flow chart of the entire process
starting from 1. human umbilical cord tissue, 2. cell isola-
tion, 3. cell cultivation in terms of primary culture, 4. cell
harvest, leading to the final cell product prepared for 5.
cryopreservation. The aims of the study involved conse-
quent adaption from research and development (R&D)
materials to GMP compliant starting materials concerning
the cell isolation, cultivation and cryopreservation process.
Furthermore, especially the influence of long term cryo-
preservation should be studied to control if the cells are
applicable for future long term storage in GMP-certified
cell banks. To satisfy requirements of GMP, quality con-
trols should be established by performing extensive
phenotypic and functional cell analysis.Table 1 Replacement of R&D starting materials to GMP comp
R&D starting materials
Enzymes Dispase II (Roche Diagnostics, Mannheim, Ger
Serum Fetal calf serum (Biochrom AG, Berlin, German
Supplements Penicillin/Steptomycin (Invitrogen, Carlsbad, U
Heparin (Sigma, St. Louis, USA)
Basic fibroblast growth factor (Sigma, St. Louis
Cryopreservation Fetal calf serum (Biochrom AG, Berlin, German
Dimethyl sulfoxide (Sigma, St. Louis, USA)As a long-term objective, the human vascular cell bank
could supply cells for individual autologous or allogenic
therapeutic applications such as the fabrication of tissue
engineered cardiovascular constructs.
Materials and methods
Adaption to GMP compliant starting materials
To establish protocols of cell isolation, cultivation and
cryopreservation conforming to GMP, adequate GMP
grade starting materials had to be identified at first.
Consequently, already established R&D protocols were
remodelled concerning the starting materials. A number
of R&D substances such as fetal calf serum (FCS) were
completely replaced with agents conforming to GMP
such as human AB serum (HS), because some of the
R&D substances used so far were not available in GMP
grade (Table 1). PBS and cell culture media were not
replaced with regard to the GMP certified fabrication of
the solutions (manufacturers’ instructions).
Cell isolation and cultivation
Human umbilical cords were obtained from the Depart-
ment of Obstetrics of the Charité Universitätsmedizin
Berlin. The parents were informed consent form about
the objectives of the research project and after receiving
the signed inform consent form from parents, the cords
were processed after delivery. The research was carried
out according to the principles of the Declaration of
Helsinki and the study was approved by the Ethical
Review Board at the Charité Universitätsmedizin Berlin,
Humboldt University of Berlin, Germany (186/2001).
According to the analysis of the adaption from R&D
starting materials GMP compliant materials, human um-
bilical cords of similar length were divided in half and
HUVEC as well as HUCAC were isolated, cultivated and
harvested according to R&D and GMP conditions in par-
allel (Table 1).
After washing the cord with Dulbecco’s phosphate buf-
fered saline (PBS) (Invitrogen, Carlsbad, USA) the vein
was filled with 2.4 U/ml dispase II solution (Rocheliant starting materials
GMP starting materials
many) Collagenase NB6 (Serva, Heidelberg, Germany)
y) Human serum (pooled AB serum, Centre for
Clinical Transfusion Medicine Tuebingen, Germany)
SA)
, USA)
Gentamicin (PAA, Pasching, Austria) Heparin
(pharmaceutical grade, Ratiopharm, Ulm, Germany)
Basic fibroblast growth factor (clinical grade,
Peprotech, Hamburg, Germany)
y) Human serum albumin (20 %, pharmaceutical grade,
Baxter, Unterschleißheim, Germany)
Dimethyl sulfoxide (pharmaceutical grade,
Charité- Universitätsmedizin Berlin, Germany,
product of the dispensary)
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30 min in a humidified atmosphere of 37°C and 5 %
CO2 for isolation of HUVEC according to conventional
R&D conditions. Under GMP conditions, 0.12 U/ml col-
lagenase NB6 solution (Serva, Heidelberg, Germany) was
injected into the vein and incubated for 20 min. In accor-
dance with R&D conditions, collected HUVEC were cul-
tured in Medium 199 (Invitrogen) supplemented with
10 % FCS (Biochrom AG, Berlin, Germany), 1 % penicillin/
streptomycin (Invitrogen), 5 U/ml heparin (Sigma, St.
Louis, USA) and 10 ng/ml basic fibroblast growth fac-
tor (bFGF, Sigma) at 37°C in a 5 % CO2 atmosphere. To
achieve conditions conforming to GMP, Medium 199 was
supplemented with 10 % HS (pooled AB serum, Centre
for Clinical Transfusion Medicine Tuebingen, Germany),
1 % gentamicin (PAA, Pasching, Austria), 5 U/ml heparin
(pharmaceutical grade, Ratiopharm, Ulm, Germany) and
10 ng/ml bFGF (Peprotech, Hamburg, Germany). The fol-
lowing day, the HUVEC were washed with PBS to remove
all non-adherent cells. At confluence, the cells were trypsi-
nized (0.05 % trypsin/0.02 % EDTA, Invitrogen) and then
cryopreserved after primary culture.
HUCAC were isolated by mechanical excision. Cord
arteries were excised out of the ambient tissue, minced
into 1 mm pieces and placed in polystyrene dishes (Sar-
stedt, Nuembrecht, Germany) allowing the cells to grow
out of the arterial wall (explant culture). Under R&D
conditions, sections were cultured in Dulbecco’s modi-
fied Eagle’s medium (DMEM, Invitrogen) supplemented
with 20 % FCS and 1 % penicillin/ streptomycin (Invitro-
gen) in a humidified atmosphere of 37°C and 5 % CO2.
To obtain GMP conditions, DMEM (Invitrogen) was
supplemented with 5 % HS and 1 % gentamicin (PAA).
After approximately 21 days, sufficient cell numbers
were harvested and cryopreservation was initiated after
primary culture.
Cryopreservation and recultivation
Harvested HUCAC and HUVEC from primary culture
(passage 0) isolated with GMP compliant starting
materials were used for cryopreservation. A pellet
of about 1.0 x 106 cells was assimilated in 1 ml freezing-
media, consisting of 90 % of a 20 % human serum
albumin solution (HSA, Baxter, Unterschleißheim,
Germany) and 10 % dimethyl sulfoxide (DMSO, Charité-
Universitätsmedizin Berlin, Germany), rapidly transferred
to a cryovial (Nunc, Langenselbold, Germany) and stored
in an isopropanol bath freezing container (Nalgene,
Rochester, USA) at – 80°C for 24 hours. Isopropanol
ensures cell cooling at a steady freezing rate of −1°C/min
down to −80°C. Finally, cells were placed in the vapour
phase of liquid nitrogen for short-term (7 days) and
long-term (1 year) storage. After the cryopreservation
period the cells were rapidly thawed by immersing thevials in a water bath for 2 min at 37°C. Cells were resus-
pended in culture medium, centrifuged at 360 x g for
6 min to remove residual DMSO, and recultivated in a
humidified atmosphere of 37°C and 5 % CO2 for subcul-
tivation. Cell culture medium was replaced every 2–
3 days.
Cell viability
Viability of short-term cryopreserved HUCAC (group A:
n = 5) and HUVEC (group A: n = 4) and long- term cryo-
preserved HUCAC (group B: n = 4) and HUVEC (group
B: n = 5) from primary cultures was studied after the
thawing process and in the first passage of recultivation.
Non-cryopreserved fresh cultivated HUCAC (n = 5) and
HUVEC (n = 4) were analyzed in parallel as control
groups. The cells were resuspended in appropriate cell
culture medium and diluted with trypan blue solution
(1:1). Unstained cells were counted as viable cells by
using a hemacytometer. Cell viability is calculated by the
number of viable cells divided by the number of total
cells in percent.
Proliferation potential
Proliferation potential of short-term cryopreserved
HUCAC (group A: n = 3) and HUVEC (group A: n = 4)
and long-term cryopreserved HUCAC (group B: n = 3)
and HUVEC (group B: n = 5) was quantified using a col-
orimetric water soluble tetrazolium assay (WST-1, Roche
Diagnostics, Mannheim, Germany). Non-cryopreserved
fresh cultivated HUCAC (n = 3) and HUVEC (n = 4)
were analyzed in parallel as control groups. The cells
were seeded in 96-well plates at a concentration of 2.0 x
103 cells/well and cultivated in appropriate cell culture
medium at 37°C in a 5 % CO2 atmosphere. Culture
medium was changed every 2–3 days. On days 0, 1, 2, 3,
4 and 7 10 μl WST-1 solution was added to 100 μl sam-
ple supernatant (quintuplicates) and incubated for 2 h at
37°C. This procedure was repeated for cells of passages
2–5. The optical density (OD) of supernatants was mea-
sured against a background control as blank (culture
medium without cells) at 450 nm using an absorbance
microplate reader (Biotek, Bad Friedrichshall, Germany).
Reference wavelength of 630 nm was subtracted from
averaged OD values measured at 450 nm. Growth curves
for direct and quantitative analysis of proliferation were
created. The OD values obtained were correlated to the
number of living cells, i.e. the higher the OD values, the
higher the cell number.
Flow cytometry analysis
Surface and intracellular marker expression of fresh cul-
tivated HUCAC (control group: n = 3) and HUVEC
(control group: n = 3), short-term cryopreserved HUCAC
(group A: n = 4) and HUVEC (group A: n = 4) and long-
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HUVEC (group B: n = 4) was detected by flow cytometry
analysis. Single cell suspensions of 1.4 x 105 cells in
100 μl 2 % fetal bovine serum/PBS were prepared from
HUCAC and HUVEC of primary culture (passage 0),
passage 3 and 4. Single- and multi-color stainings were
performed using fluorescein isothiocyanate (FITC),
phycoerythrin (PE) or allophycocyanin (APC) conjugated
mouse monoclonal antibodies. Corresponding isotype
immunoglobulins were used as negative controls for
each antibody.
First multi-color staining was performed by incubating
HUCAC with anti-human CD44-FITC (1:20, Beckman
Coulter, Krefeld, Germany), anti-human CD166-PE
(2.5 μg/ml, R&D Systems, Minneapolis, USA) and anti-
human CD105 –APC (2.5 μg/ml, R&D Systems) for
45 min at 4°C after blocking with Fc-blocking reagent
(Miltenyi Biotec, Teterow, Germany). Second multi-
color staining was performed by incubating HUCAC
with anti-human CD90-FITC (1:20, Beckman Coulter),
anti-human CD29-APC (1:20, BD Biosciences, Heidel-
berg, Germany) and anti-human CD73-PE (1:20, BD
Biosciences) for 45 min at 4°C. Single-color staining to
intracellular human ASMA (PE-conjugated, 2.5 μg/ml,
R&D Systems) was performed for 45 min at room
temperature (RT) after fixation and permeabilization
with Intra Präp Kit (Beckman Coulter).
Single-color staining was performed by incubating
HUVEC with anti-human CD146-APC (10 μg/ml, Milte-
nyi Biotec) for 10 min at 4°C. Multi-color staining to
anti-human CD105-APC (2.5 μg/ml, R&D Systems) and
anti-human CD31-FITC (20 μg/ml, BD Biosciences) was
performed for 45 min at 4°C. After fixation and
permeabilization with the Intra Präp Kit (Beckman
Coulter) anti-human CD144-PE (20 μg/ml, Beckman
Coulter) was added for 15 min at RT. Accordingly, the
cells were washed twice with PBS, fixed in 2 % para-
formaldehyde solution and analyzed by using a flow
cytometer (Beckman Coulter).
Immunofluorescence staining
Expression of cellular marker molecules and production
of different ECM proteins were qualitatively analyzed by
indirect immunofluorescence staining. Fresh cultivated
and cryopreserved HUCAC (each n= 3) and HUVEC
(each n = 3) were seeded onto glass coverslips and fixed
with ice-cold methanol/acetone solution (1:1) after
reaching confluence. HUCAC were incubated with
primary monoclonal mouse antibodies against human
CD90 (4 μg/ml, Dianova, Hamburg, Germany), human
CD105 (10 μg/ml, BD Biosciences, Heidelberg, Germany),
human CD29 (625 ng/ml, BD Biosciences), human CD44
(5 μg/ml, BD Biosciences), human fibronectin (5 μg/ml,
BD Biosciences) and with polyclonal rabbit antibodyagainst human ASMA (25 μg/ml, Abcam, Cambridge,
UK), human collagen types I & III (0.5 μg/ml, Acris Anti-
bodies, Herford, Germany), human elastin (1:50, Calbio-
chem, Darmstadt, Germany) and smoothelin (3.6 μg/ml,
Abcam) for 3 h at 4°C. HUVEC were incubated with
monoclonal mouse antibodies against human CD31 (1:50,
Sigma, St.Louis, USA), human CD144 (10 μg/ml, BD
Biosciences), human CD146 (25 μg/ml, BD Biosciences),
human vWF (8 μg/ml, Millipore, Billerica, USA) and
with polyclonal rabbit antibody against human eNOS
(12.5 μg/ml, BD Biosciences) and ASMA (25 μg/ml,
Abcam) for 3 h at 4°C. After incubation with primary
antibodies, cells were washed three times with PBS,
followed by incubation with appropriate FITC/TRITC
conjugated secondary anti-mouse/rabbit antibodies (1:400,
Invitrogen, Carlsbad, USA) for 2 h at RT. Fixed cross
sectioned umbilical cord arteries were used to localize
HUCAC and served as controls by staining with mono-
clonal mouse anti-human CD90 (4 μg/ml, Dianova),
anti-human fibronectin (5 μg/ml, BD Biosciences) and
with polyclonal rabbit anti-human ASMA (25 μg/ml,
Abcam), anti-human collagen types I & III (0.5 μg/ml,
Acris Antibodies), anti-human elastin (1:50, Calbiochem)
for 3 h at 4°C. Cross sections of umbilical cord vein
served also as controls and were incubated with mono-
clonal mouse anti-human CD31 (1:50, Sigma) and anti-
human vWF (8 μg/ml, Millipore) for 3 h at 4°C to detect
HUVEC. Subsequently, staining with corresponding sec-
ondary FITC/TRITC labelled anti-mouse/rabbit anti-
bodies (Molecular Probes, Eugene, USA) was performed.
Cell nuclei were stained with DAPI (Roche Diagnostics,
Mannheim, Germany) for 10 min at RT and finally cells
and cross sections were mounted with Mowiol mounting
medium (Calbiochem).
Immunohistochemical staining
Expression of cellular marker molecules and production
of different ECM proteins was qualitatively analyzed by
immunohistochemical staining. Stainings were automat-
ically performed in a Bond-MAX stainer (Leica, Wetzlar,
Germany). Fixed cross sectioned umbilical cord arteries
were used to localize ECM proteins and served as con-
trols by staining with monoclonal mouse anti-human
collagen type I (0.5 μg/ml, Acris Antibodies, Herford,
Germany), anti-human collagen type III (30 μg/ml, Inno-
vative Diagnostics, Vienna, Austria) and anti-human
elastin (1:100, Sigma, St.Louis, USA) for 30 min at RT
after blocking with goat serum (10 %, Leica) for 10 min.
Cross sections of umbilical cord vein, serving as
controls, were incubated with monoclonal mouse anti-
human CD31 (1:80, Innovative Diagnostics) and anti-
human vWF (1:100, Dako, Hamburg, Germany) for
30 min to detect HUVEC after blocking with goat serum
(10 %, Leica) for 10 min. Sections were rinsed with
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sponding secondary alkaline phosphatase-labelled anti-
bodies (Detection Kit, Leica) for 10 min. After rinsing
with washing solution (10 %, Leica), enzyme substrate
(Polymer AP Red Detection Kit, Leica) was added for
20 min. Counterstaining was performed for 3 min using
hematoxyline staining solution (30 %, Thermo-Shandon,
Frankfurt, Germany) to visualize cell nuclei. Finally, cross
sections were dehydrated with 90 % and 100 % alcohol
solution and subsequently embedded in mounting medium
(Cytoseal XYL, Thermo Scientific, Waltham, USA).
Differentiation potential
Differentiation potential of fresh cultivated HUCAC
from passage 2 (n = 3) and 4 (n = 3) was studied using a
multilineage method including analysis of osteogenic,
chondrogenic and adipogenic differentiation potential
[27]. Bone marrow derived mesenchymal stem cells
(MSC) from passage 2 (n = 1) and 4 (n = 1) were anal-
yzed in parallel, serving as positive controls. Analysis of
differentiation potential was performed according to
R&D conditions.
Osteogenesis
Cells were stimulated with osteogenic medium, consist-
ing of DMEM (1 g/l Glucose, Invitrogen, Carlsbad, USA)
supplemented with 5 % FCS (Biochrom AG, Berlin,
Germany), 1 % penicillin/streptomycin (10,000 U/
10,000 μg/ml, Invitrogen), 100 nM dexamethasone
(Sigma, St.Louis, USA), 10 mM ß-glycerophosphate
(Sigma), 0.17 mM L-ascorbic-acid (Sigma), for at least
28 days.
Medium was changed every 2–3 days. To detect the
mineralization process, calcium accumulations were
stained by the Von Kossa method. Cells were fixed with
iced methanol for 30 min at −20°C, washed with sterile
water and treated with 5 % silver nitrate solution (Sigma)
for 30 min at RT with absence of light. Finally, 5 %
sodium bicarbonate solution (Sigma) supplemented with
1 % formaldehyde (37 %, Sigma, Germany) was used to
detect calcium accumulations. The surface enzyme alka-
line phosphatase, whose activity is increased on osteo-
blasts [28], was detected by BCIP/NBT staining solution
(Roche Diagnostics, Mannheim, Germany). The fixed
cells were stained for 10 min at RT by absence of light
and washed with distilled water.
Adipogenesis
Adipogenic differentiation was induced by incubating the
cells with DMEM (4.5 g/l glucose, Invitrogen) supple-
mented with 10 % FCS (Biochrom AG), 1 % penicillin/
streptomycin (10,000 U/10,000 μg/ml, Invitrogen),
0.01 mg/ml insulin (Insuman Comb 25, Sanofi Aventis-
40 I.E./ml, Germany), 0.2 mM indomethacine (Sigma),0.5 mM 3-isobutyl-1-methyl-xanthine (IBMX) (Sigma),
1 μM dexamethasone (Sigma) for at least 25 days. The
stimulation process was performed in 3–4 cycles. One
cycle lasted 5 days, in which the cells were stimulated
with adipogenic medium for the first 3 days and for the
remaining 2 days with adipogenic medium without
stimulating factors. To detect fat cell-specific enhanced
lipid vacuoles the cells were stained with 0.5 % Oil
Red O solution (Sigma), a liposoluble dye which stains
triglycerides.
Chondrogenesis
High dense micromass pellet cultures composed of
agglomerated HUCAC were generated in 15 ml centri-
fuge tubes (0.4 x 106 cells/tube) and stimulated with
serum-free DMEM (4.5 g/l glucose, Invitrogen) culture
medium supplemented with 1 % penicillin/streptomycin
(10000 U/10000 μg/ml, Invitrogen), 1 % ITS+ 1 supple-
ments (Sigma), 100 nM dexamethasone (Sigma), 1 mM
sodium pyruvate (Invitrogen); 0.17 mM L-ascorbic-acid
(Sigma); 0.35 mM proline (Sigma) and 10 ng/ml TGFß-3
(Promocell, Heidelberg, Germany) for at least 28 days.
Medium was changed every 2–3 days. To detect
cartilage-specific collagen type II, cross-sectioned micro-
mass cell pellets (HUCAC) were stained with rabbit
polyclonal anti-human collagen II (1:40, Leica, Wetzlar,
Germany) and specific proteoglycans (aggrecan) were
visualized by Alcian PAS staining.
All staining analyses were performed using bright field
light microscopy.
Statistical analysis
All experiments were performed at least in triplicate.
Results were expressed as mean values ± standard devi-
ation. Statistical analysis was performed by using Graph
Pad Prism (Version 5.01). Comparisons between recul-
tivated, cryopreserved cells (group A and B) and fresh
cultivated cells (control group) were done using
Student’s t-test. Differences were considered statistically
significant at P< 0.05.
Results
Adaption to GMP compliant starting materials
Adaption from conventional R&D starting materials to
GMP compliant starting materials was studied concern-
ing cell isolation and subsequent cell cultivation (pri-
mary culture). HUCAC quickly grew out of single
explant pieces and showed robust spindle-shaped
morphology in primary cultures (Figure 1A). HUVEC
demonstrated a rounded, cobblestone-like morphology
(Figure 2A). Comprehensive homogenous confluence
arising from initial scattered colonies (Figure 2A) was
observed in primary culture. No significant morpho-
logical differences were observed for HUCAC and
Figure 1 Outgrowth and viability of human umbilical cord
artery derived cells (HUCAC). A) HUCAC isolated by mechanical
excision grew out of single cord artery pieces (explant culture) after
approximately 21 days and demonstrated robust spindle-shaped
morphology in primary cultures (passage 0). Cells from primary
cultures were used for further cryopreservation studies. Viability of
short-term (group A, n = 5) and long-term (group B, n = 4)
cryopreserved cells from primary cultures (passage 0) was studied
directly after B) thawing and C) in passage 1 of recultivation using
trypan blue staining assay. By comparison, non-cryopreserved fresh
cells (n = 5) from primary cultures and passage 1 were analyzed in
parallel as control group. The number of viable cells divided by the
number of total cells results in cell viability (%).
Figure 2 Growth colony formation and viability of human
umbilical vein endothelial cells (HUVEC). A) Enzymatically isolated
HUVEC first grew in scattered colonies and demonstrated typical
rounded, cobblestone-like morphology. After reaching confluence in
primary cultures (passage 0) cells were used for further
cryopreservation studies. Viability of short-term (group A, n = 4) and
long-term (group B, n = 5) cryopreserved cells from primary cultures
(passage 0) was studied directly after B) thawing and C) in passage
1 of recultivation using trypan blue staining assay. By comparison,
non- cryopreserved fresh cells (n = 4) from primary cultures and
passage 1 were analyzed in parallel as control group. The number of
viable cells divided by the number of total cells results in cell
viability (%).
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GMP protocols.
Using R&D protocol, 6.8 x 106 ± 2.2 x 106 HUCAC
(n = 4) and 3.0 x 106 ± 0.6 x 106 HUVEC (n = 4) wereobtained from primary cultures. Similar cell numbers
were harvested for each cell type using the GMP proto-
col: HUCAC (n = 4): 7.0 x 106 ± 1.3 x 106 and HUVEC
(n = 4): 3.8 x 106 ± 1.2 x 106.
Figure 3 Proliferation potential of human umbilical cord artery
derived cells (HUCAC). Significant morphological differences were
not observed for A) fresh cultivated and B) cryopreserved HUCAC.
C) Proliferation potential of recultivated short-term (group A, n = 3)
and long-term (group B, n = 3) cryopreserved cells was quantified
using a colorimetric WST-1 assay. By comparison, non- cryopreserved
fresh cells (n = 3) were analyzed in parallel as a control group (C).
The optical density (OD) was measured at 450 nm and reference
wavelength of 630 nm was subtracted. OD values were correlated to
the number of living cells and higher OD values meant a higher cell
number. Morphology and proliferation potential are exemplarily
shown for cells of passage 3.
Polchow et al. Journal of Translational Medicine 2012, 10:98 Page 8 of 17
http://www.translational-medicine.com/content/10/1/98Cell viability
Cell viability of short-term cryopreserved (group A) and
long-term cryopreserved (group B) cells was directly
measured after thawing and in passage 1 of recultivation
using the trypan blue assay. Fresh cells were analyzed in
parallel as a control group. After the thawing process,
the viability of group A and B HUCAC was decreased
to 67.4 ± 7.6 % and 63.8 ± 3.6 % and significantly low-
er (P = 0.011, P = 0.015) than the viability of fresh cul-
tivated cells (control group) from primary cultures
(84.4 ± 9.4 %), shown in Figure 1B. Already in passage 1,
cell viability of recultivated cryopreserved HUCAC from
group A (82.4 ± 2.2 %) and B (80.7 ± 2.2 %) increased and
was comparable to the viability of the control group
(81.2 ± 3.7 %), represented in Figure 1C. No significant
difference in cell viability was detected by comparing the
control group with group A (P = 0.625) and the control
group with group B (P = 0.694) in passage 1.
Viability of HUVEC from group A and B was about
66.3 ± 8.8 % and 69.2 ± 4.6 %, directly determined after
the thawing process (Figure 2B). Fresh cultivated cells
(control group) demonstrated higher viabilities of about
86.3 ± 8.6 %. Thus, significant differences in cell viability
were detected by comparing group A (P = 0.024) and B
(P = 0.023) to the control group. Increased viabilities of
HUVEC from group A and B were detected in passage 1
(80.7 ± 3.4 % and 78.2 ± 1.1 %), similar to the viability of
control group cells (78.0 ± 1.8 %) (Figure 2C). Accord-
ingly, comparing cell viability of the control group with
group A (P = 0.295) and with group B (P = 0.815) no sig-
nificant differences were detected.
Proliferation potential
Proliferation potential of short-term cryopreserved
(group A) and long-term cryopreserved (group B) cells
was measured for several passages, using the WST-1
proliferation assay. Fresh cells were cultivated in parallel
as a control group. A continuous increase in cell number
was detected for all tested groups of HUCAC with max-
imal absorbance on day 7, exemplarily shown for pas-
sage 3 (Figure 3C). Related to initial absorbance (day 0),
a 22.1-fold, 23.1-fold and 13.6-fold increase was detected
for the control group, group A and group B on day 7
(Figure 3C). No significant difference in proliferation
was detected for the control group and group A from
day 0 (P = 0.421) to day 7 (P = 0.066) in culture. How-
ever, comparing group B HUCAC to the control group,
a significant difference in proliferation was determined
from day 1 (P = 0.022) to day 4 (P = 0.010), but not on
day 7 (P = 0.059). After a short lag phase, increased
absorbance was detected for all tested groups of
HUVEC, starting from day 1 to day 7 with maximal
absorbance on day 4 (control group) and day 7 (group A,
B), exemplarily shown for passage 3 (Figure 4C).In relation to the initial absorbance value, a 11.2-fold,
11.5-fold and 7.7-fold increase was measured for control
group, group A and group B. Comparing the prolifera-
tion potential of the control group and group A, no
Figure 4 Proliferation potential of human umbilical vein
endothelial cells (HUVEC). Significant morphological differences
were not observed for A) fresh cultivated and B) cryopreserved
HUVEC. C) Proliferation potential of recultivated short-term (group A,
n = 4) and long-term (group B, n = 5) cryopreserved cells was
quantified using a colorimetric WST-1 assay (C). By comparison,
non- cryopreserved fresh cells (n = 4) were analyzed in parallel as a
control group. The optical density (OD) was measured at 450 nm and
reference wavelength of 630 nm was subtracted. OD values were
correlated to the number of living cells and the higher OD values
meant a higher cell number. Morphology and proliferation potential
are exemplarily shown for cells of passage 3.
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to day 7 (P = 0.182). However, the proliferation potential
of HUVEC from group B was significantly lower than
that of the control group from day 1 (P = 0.039) until day3 (P = 0.021), but not on day 4 (P = 0.0543) or day 7
(P = 0.078).
Altogether, similar trends of growth curves were deter-
mined for recultivated cryopreserved (group A and B) and
fresh cultivated (control group) HUCAC and HUVEC.
Additionally, no significant morphological differences
were observed for fresh cultivated HUCAC (Figure 3A)
and cryopreserved HUCAC (Figure 3B) or for fresh culti-
vated HUVEC (Figure 4A) and cryopreserved HUVEC
(Figure 4B), exemplarily shown for fresh cultivated and
short-term cryopreserved cells of passage 3.
Expression of cellular markers
Expression of cellular markers of short-term cryopre-
served (group A) and long-term cryopreserved (group B)
cells was studied after thawing and in passage 3 and 4 of
recultivation by flow cytometry analysis and indirect im-
munofluorescence staining. Fresh cultivated cells from
passage 0, 3 and 4 were studied in parallel as a control
group. Results of flow cytometry analysis revealed that
HUCAC are positive for ASMA and CD90 as well as for
the markers of mesenchymal stem cells such as CD44,
CD166, CD105, CD73 and CD29. Directly after thawing,
cellular marker expression of cells from group A and B
was decreased compared to expression levels of the con-
trol group (Figure 5 I). Especially, expression of the
intracellular marker protein ASMA was reduced to
levels of about 62.5 ± 33.3 % (group A) after the thawing
process. Nevertheless, no significant difference in marker
expression was detected for HUCAC from group A and
B compared to the control group, regarding all tested
markers (P> 0.05). Recultivated cells from group A and
B demonstrated increased expression levels of cellular
markers, nearly or completely achieving levels of mar-
kers expressed by fresh cultivated cells (control group),
exemplarily shown for passage 3 in Figure 5 J. The dif-
ference in expression levels for all tested cellular mar-
kers was not significant for cells of group A and B
compared to the control group (P> 0.05).
Endothelial cell specific markers such as CD146,
CD31, CD105 were highly expressed by fresh cultivated
HUVEC (control group). Lower value of expression
was detected for CD144 (about 86.9 ± 7.8 %), shown in
Figure 6 I. In comparison with the control group,
expression of CD31 was decreased to levels of about
82.6 ± 9.4 % (group A) and 78.0 ± 10.3 % (group B), mea-
sured directly after thawing. Cells from group B demon-
strated significantly decreased expression of CD144
(27.8 ± 11.5 %, P = 0.036), as well. However, expression of
CD146 and CD105 remained stable for HUVEC from
group A and B after thawing. In passage 3, almost all
endothelial cell specific markers were still highly
expressed by HUVEC from group A and B and achieved
the expression levels of the control group (Figure 6 J).
Figure 5 (See legend on next page.)
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Figure 5 Expression of cellular marker molecules and extracellular matrix (ECM) proteins by human umbilical cord artery derived cells
(HUCAC). Using indirect immunofluorescence staining, highly positive signals (green) were detected for A) collagen type I of fresh cultivated cells
and B) collagen type I of cryopreserved cells, E) collagen type III of fresh cultivated cells and F) collagen type III of cryopreserved cells. The
presence of C) collagen type I (green) and G) collagen type III (green) was shown in native human umbilical cord artery walls, serving as a
control. Immunohistochemical staining verified the presence of D) collagen type I (red) and H) collagen type III (red) in native human umbilical
cord artery walls. Using flow cytometry analysis, cellular marker expression of short-term (group A, n = 4) and long-term (group B, n = 4)
cryopreserved cells from primary cultures (passage 0) was studied directly after I) thawing and J) in passage 3 of recultivation. By comparison,
non-cryopreserved fresh cells (n = 3) from I) primary cultures and J) passage 3 were analyzed in parallel as a control group Using indirect
immunofluorescence staining, highly positive signals (green) were detected for all cellular markers tested such as K) CD90 (green)/ alpha smooth
muscle actin (ASMA) (red) of fresh cultivated cells and L) CD90 (green)/ ASMA (red) of cryopreserved cells, N) CD29 of fresh cultivated cells and
O) CD29 of cryopreserved cells, P) CD105 of fresh cultivated cells and Q) CD105 of cryopreserved cells. Cell nuclei staining is pictured in blue,
present in A-H and K-Q. All studies of marker expression are exemplarily shown for cells of passage 3.
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pression was detected for group A and B compared to
control group (P> 0.05). Only HUVEC from group B
still demonstrated low expression of CD144, significantly
different from the control group (P = 0.009).
Indirect immunofluorescence studies were performed
to verify the results of flow cytometry analysis and are
exemplarily shown for fresh cultivated (control group)
and recultivated short-term cryopreserved (group A)
HUCAC and HUVEC from passage 3. Intense positive
signals were detected for HUCAC stained with anti-
CD44 (data not shown), anti-CD105 (Figure 5 P, Q) and
anti-CD29 (Figure 5 N, O). Double staining against
CD90 and ASMA revealed that a single cell expresses
both markers simultaneously (Figure 5 K, L).The pres-
ence of CD90 and ASMA was also detected in human
umbilical cord artery walls (Figure 5 M). No difference
in signal intensity was observed for HUCAC from the
control group and group A. Smoothelin, a late differenti-
ation marker of contractile smooth muscle cells, was not
expressed by HUCAC (data not shown). ECM proteins
such as collagen I, III, fibronectin (data not shown) and
elastin (data not shown) were expressed by HUCAC
from the control group and group A with no difference
in signal intensity (Figure 5 A, B, E, F). These proteins
were also detected in native human umbilical cord arter-
ies represented in Figure 5 C, D, G, H.
Positive signals were detected for CD31 (Figure 6 A,
B), vWF (Figure 6 E, F), CD144 (Figure 6 K, L), CD146
(data not shown) and eNOS (Figure 6 M, N) with no
evident difference in fluorescence intensity between
HUVEC from the control group and group A. Presence
of CD31 and vWF was also detected in endothelium of
the human umbilical vein (figure C, D and G, H).
HUVEC were negative for ASMA (data not shown).
Analysis of differentiation potential
To extend characteristic analysis for HUCAC, differenti-
ation studies were performed to analyze whether the
cells have the potential to differentiate into other cell
types. Differentiation potential was examined in passage2 and passage 4 fresh cultivated HUCAC and MSC from
bone marrow (positive controls). Increased alkaline
phosphatase activity and bone-specific calcified matrix
areas (Von Kossa staining) were not detected for stimu-
lated HUCAC compared to MSC (Figure 7 A, B, C and
D, E, F). Furthermore, cartilage-specific collagen II and
proteoglycans (Alcian PAS staining) were not detected
for stimulated cells (Figure 7 J, K and M, N). By contrast,
MSC have the potential to differentiate into chondro-
cytes, because red stained collagen II and blue stained
proteoglycans were apparent (Figure 7 L, O). Controver-
sial staining results with Oil Red O were obtained for
adipogen-stimulated HUCAC, because 2 of 6 samples
showed few enlarged lipid vacuoles (Figure 7 G, H, I),
whereas no significant difference in number and size
of adipose tissue-specific lipid vacuoles was detected
for unstimulated and stimulated HUCAC in remaining
samples. Altogether, multilineage differentiation potential
of stimulated HUCAC was not demonstrated uniformly.
Discussion
The human umbilical cord represents a potential cell
source for cardiovascular tissue engineering because it is
easily available after delivery without additional surgical
intervention for the patient, ethically acceptable and offers
adequate tissue mass. Cells derived from human umbilical
cord vessels became of interest for cardiovascular tissue
engineering since few years [12,17]. The aim of the recent
study was to develop first essential strategies for establish-
ing an individual cell bank consisting of vascular cells
from the human umbilical cord under GMP conditions.
Adaption from R&D starting materials to GMP com-
pliant starting materials was studied because only
starting materials produced conforming to GMP are
allowed to be used for the fabrication of cell products
and medicinal products for subsequent clinical applica-
tions. Consequently, already established R&D protocols
for cell isolation and cultivation were remodelled con-
cerning to starting materials. Sufficient numbers of
harvested HUCAC and HUVEC from primary cultures
demonstrated that the cell isolation process was
Figure 6 Expression of cellular marker molecules by human umbilical vein endothelial cells (HUVEC). Using indirect immunofluorescence
staining, highly positive signals (green) were detected for A) CD31 of fresh cultivated cells and B) CD31 of cryopreserved cells, E) von Willebrandt
factor (vWF) of fresh cultivated cells and F) vWF of cryopreserved cells. The presence of C) CD31 (green) and G) vWF (green) was detected in the
endothelium of native human umbilical cord veins, serving as a control. Immunohistochemical staining verified the presence of D) CD31 (red)
and H) vWF (red) in the endothelium of native human umbilical cord veins. Using flow cytometry analysis, cellular marker expression of short-
term (group A, n = 4) and long-term (group B, n = 4) cryopreserved cells from primary cultures (passage 0) was studied directly after I) thawing
and J) in passage 3 of recultivation. By comparison, non-cryopreserved fresh cells (n = 3) from I) primary cultures and J) passage 3 were analyzed
in parallel as a control group. Using indirect immunofluorescence staining, highly positive signals (green) were also detected for the cellular
markers K) CD144 of fresh cultivated cells and L) CD144 of cryopreserved cells, M) endothelial nitric oxide-synthase (eNOS) of fresh cultivated
cells and N) eNOS of cryopreserved cells. Cell nuclei staining is pictured in blue, present in A-H and K-N. All studies of marker expression are
exemplarily shown for cells of passage 3.
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in isolation of similar cell numbers as using R&D pro-
tocols. Cell morphologies were monitored during pri-
mary cultures and expression of cellular markermolecules was analyzed after cell isolation in order to
test whether desired cell types are obtained. Subse-
quently, fresh harvested cells from primary cultures
(passage 0) were used for cryopreservation. After the
Figure 7 (See legend on next page.)
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Figure 7 Differentiation potential of human umbilical cord artery derived cells (HUCAC) compared with mesenchymal stem cells (MSC).
Multilineage differentiation potential of HUCAC from passage 2 (n = 3), passage 4 (n = 3) and MSC (positive control) from passage 2 (n = 1),
passage 4 (n = 1) was qualitatively analyzed by histological and immunohistochemical staining methods. Osteogenic differentiation potential was
studied by histological Von Kossa staining: A) unstimulated HUCAC (day 28), B) stimulated HUCAC (day 28), C) stimulated MSC (day 28) and
histological alkaline phosphatase staining: D) unstimulated HUCAC (day 28), E) stimulated HUCAC (day 28), F) stimulated MSC (day 28).
Adipogenic differentiation potential was studied by histological Oil Red O staining: G) unstimulated HUCAC (day 25), H) stimulated HUCAC
(day 25), I) stimulated MSC (day 25). Chondrogenic differentiation potential was studied by histological Alcian PAS staining: J) unstimulated
HUCAC (day 28), K) stimulated HUCAC (day 28), L) stimulated MSC (day 28) and by immunohistochemical collagen type II staining: M)
unstimulated HUCAC (day 28), N) stimulated HUCAC (day 28), O) stimulated MSC (day 28).
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expression of cellular markers and proliferation poten-
tial were studied in order to analyze whether the cells
maintain their characteristics and, finally, whether they
are still suitable for intended application for a vascular
cell bank.
Sufficient levels of viability were determined for har-
vested HUCAC (84.4 ± 9.4 %) and HUVEC (86.3 ± 8.6 %)
from primary culture. Cell viability of cryopreserved cells
was decreased directly after the thawing process, but
already increased in passage 1 and achieved the viability
of fresh cultivated cells. It was found that the short-term
and long-term cryopreservation process did not influ-
ence cell viability or cell morphology with long-lasting
impact. In morphological study, fresh cultivated and cryo-
preserved HUCAC demonstrated an elongated spindle-
shaped morphology, also demonstrated in previous
studies [16,17]. Endothelial cell-specific cobblestone like
morphology observed for HUVEC in the present study
was similarly demonstrated for HUVEC in a study by
Ulrich-Merzenich et al. [29].
Cytoskeletal filament protein ASMA and cell surface
protein CD90 were highly expressed by fresh cultivated
HUCAC (control group). Correspondingly, high CD90
and ASMA expression was also described for fresh iso-
lated human umbilical cord artery derived cells in stud-
ies by Schäfermeier et al. [15]. In the present study,
expression of CD90 and ASMA was tested for reculti-
vated short- and long- term cryopreserved cells, showing
no significant difference in expression compared to fresh
cultivated HUCAC. Both markers were also analyzed for
cryopreserved myofibroblasts from human umbilical
cord by immunofluorescence staining in previous studies
[16,17]. Besides, here we demonstrated that nearly every
single HUCAC expressed fibroblast-specific CD90 and
smooth muscle cell-specific ASMA simultaneously.
Smoothelin, an exclusively expressed marker in fully dif-
ferentiated contractile smooth muscle cells [30], was not
detected for HUCAC. Positive signals were also detected
for extracellular matrix proteins such as collagen types I
and III, elastin and for the glycoprotein fibronectin,
proving that HUCAC are able to produce ECM compo-
nents also found in native cord artery cross sections.
These three last mentioned aspects suggest a highsimilarity of HUCAC, isolated with GMP compliant
starting materials in the present study, to myofibroblasts
- an intermediate cell type between smooth muscle cells
and fibroblasts. These findings correspond to studies by
Schäfermeier et al. and simultaneously showed that
HUCAC are similar to pulmonary heart valve interstitial
cells and therefore present a potential cell source for
cardiovascular tissue engineering [15]. Furthermore,
HUCAC are highly positive for CD44, CD166, CD105,
CD73, CD29 and CD90 as well, also known as markers
of MSC [31]. This is attributed to their common mesen-
chymal origin because stromal cells such as fibroblasts
and myofibroblasts as well as bone marrow derived stro-
mal stem cells are cell components of the lamina pro-
pria, a thin layer of loose connective tissue [32]. Covas
et al. analyzed subcultivated mesenchymal stromal cells
from diverse human tissue and confirmed similar marker
profiles of e.g. skin fibroblasts (sFB) and MSC from bone
marrow, concerning the expression of CD73, CD90,
CD29, CD44 and CD166 amongst others [33]. Present
differentiation experiments revealed that HUCAC do
not have the potential to differentiate into the osteo-
genic, adipogenic and chondrogenic lineage, unlike MSC
from bone marrow [31]. Finally, HUCAC shared the
marker profile of MSC but they do not have multipotent
differentiation properties indicating that HUCAC are more
differentiated cells with a more restricted differentiation
potential. Expression of cellular marker molecules was
influenced by the cryopreservation process but not funda-
mentally. The subsequent recultivation process showed
increased expression levels of cryopreserved HUCAC
with no significant differences to fresh cultivated cells and
accordingly no loss of their phenotypic characteristics.
Endothelial cell-specific markers such as CD31,
CD146, CD105, vWF and eNOS were expressed by fresh
cultivated HUVEC (control group), as confirmed by flow
cytometry analysis and immunofluorescence staining.
Existence of CD31 positive cells was observed in the
endothelial lumen lining of native umbilical cord vein
cross sections. As expected, fresh cultivated cells for
example from passage 3 were highly positive for CD31
(99.1 ± 0.12 %) and also showed strong positive signals in
immunofluorescence studies. Almost similar high pro-
portions of CD31-positive HUVEC from the umbilical
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Covas et al. (86 %, passage 3) and in immunofluorescence
studies by Schäfermeier et al. [15,33]. In the present
study, expression level of CD146- positive HUVEC was
considerable higher (passage 3: 99.8 ± 0.12 %) compared
to the expression levels of flow cytometry in studies by
Covas et al. (37 %, passage 3) [33]. Schugar et al. reported
a high percentage of CD105 expressing cells (100 %) in
the endothelial lumen of cord vessels, quantified by
immunostaining of native human umbilical cord cross
sections [34]. In the current study, similar large amounts
of CD105-positive fresh cultivated HUVEC, also isolated
from the endothelial lumen of cord vein, were found
using flow cytometry analysis. High CD144-expression
levels of about 100 % were measured in the endothelial
lumen of vessels from cross sectioned native umbilical
cords by Schugar et al. [34]. Fractions of CD144-positive
fresh cultivated cells were also shown by flow cytometry
analysis in the present study, although expression levels
were a little lower compared to CD31, CD146 and
CD105. HUVEC from the endothelium of native umbil-
ical cord vein cross sections, detected by staining with
anti-CD31 and anti-vWF, were recovered and analyzed in
cell culture again, proving that cell isolation according to
GMP compliant starting materials was precise and pure.
The cryopreservation process influenced expression of
cellular markers, but not with lasting impact for CD31,
CD146 and CD105, because expression levels of fresh cul-
tivated cells were achieved rapidly during the recultivation
process, meaning that cryopreserved HUVEC did not lose
their phenotypic characteristics. Only expression of
CD144 was still affected in recultivated cryopreserved
cells, as evident in flow cytometry studies. Contrarily, not-
able CD144-positive signals were detected for recultivated
cryopreserved HUVEC from passage 3 and the signal
intensity did not differ significantly from that of fresh
cultivated cells.
Excellent proliferation properties were determined for
fresh cultivated HUCAC, similarly demonstrated in pro-
liferation studies of myofibroblasts like cells isolated
from umbilical cord artery by Kadner et al. [8]. Prolifera-
tion potential of fresh cultivated and cryopreserved
HUCAC was comparable without significant differences,
as also reported in previous studies [16]. It was apparent
that the long-term cryopreservation process influenced
the proliferation potential of HUCAC (group B) con-
cerning the extended lag phase. However, notable expo-
nential growth was detected for long-term cryopreserved
cells (group B), even though marginally delayed. An
extended cultivation period will ensure cell numbers
comparable to those of fresh cultivated HUCAC on day
7. Sufficient proliferation potential was also demon-
strated for HUVEC. After an evident lag phase, expo-
nential growth was observed from day 1 to day 4 forfresh cultivated (control group) and short-term cryopre-
served cells (group A) leading to a stationary phase from
day 4, as similarly described in previous proliferation
studies of subcultivated HUVEC with related initial
seeding densities [35]. In comparison, the lag phase of
long- term cryopreserved cells (group B) was extended
and the following exponential growth phase was delayed
in starting, indicating that the cells required more time
to adapt to the environmental conditions than short-
term cryopreserved cells. Nevertheless, no significant
difference in proliferation was determined on day 4 and
7 for group B-HUVEC compared to the control group,
indicating that long-term cryopreserved cells would be
suitable for cardiovascular tissue engineering.
The analysis of morphology and expression of cellular
markers confirmed that the isolation process of HUCAC
and HUVEC was successful using GMP compliant start-
ing materials. Both cell types expressed their cell-specific
markers and demonstrated typical expected morpholo-
gies. Sufficient viabilities of fresh isolated HUCAC and
HUVEC suggest unhesitating application of these cells
for future cell banking. Cryopreserved cells, involving
directly thawed as well as recultivated cells, mostly
maintain the phenotypic and functional characteristics
of fresh non-cryopreserved cells. Furthermore, low
standard deviation values of recultivated cryopreserved
cells concerning proliferation and expression of cellular
markers indicated great purity of the obtained HUCAC
and HUVEC culture. Altogether, cells treated with GMP
compliant starting materials did not change their pheno-
typic or functional characteristics, the same as cells trea-
ted with R&D starting materials. The establishment of
an individual human vascular cell bank under GMP con-
ditions would be feasible by using these cells.
On the basis of the recent study, we evaluated and
established some methods to control the quality and
identity of vascular umbilical cord cells which is a funda-
mental step for fully GMP compliant production. Thus,
a specific cellular marker expression profile was estab-
lished for HUCAC and HUVEC using flow cytometry
analysis, applicable as quality control for determination
of identity before cryopreservation and future storage in
the cell bank. Standardized protocols taken as a basis for
standard operating procedures (SOP) were generated
for the entire in vitro fabrication process for detailed
description of each single working step within cell isola-
tion, cell cultivation, cell harvest and cyopreserva-
tion process, ensuring accuracy and reproducibility for
intended validation procedures.
Certainly, the granting of a GMP manufacturing
authorization according to }13 German Drug Act for
banking of the described cell types needs further efforts,
such as establishing additional quality controls for
microbiological safety, purity and in vitro potency. The
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European Pharmacopoeia / ICH Q2A/B, the qualifica-
tion of umbilical cord procurement centers according to
}20b German Drug Act including serological testing and
a process validation according to annex 15 of the EU
GMP Guideline.
Finally, for future therapeutic applications of cryopre-
served HUCAC and HUVEC for tissue engineered car-
diovascular constructs, the fabrication process of the
constructs also has to be adapted to GMP conditions,
because cell-based medicinal products (ATMP) for clin-
ical trials have to be used in compliance with the prin-
ciples of GMP, formulated in Commission Directive
2003/94/EC.
Conclusion
The current study demonstrates first basic approaches
which are important for the future establishment of a
cell bank consisting of vascular cells from the human
umbilical cord. Such a cell bank would offer great bene-
fit especially for individual autologous therapeutic appli-
cations in terms of cell-based ATMP such as tissue
engineered cardiovascular constructs. The fabrication of
a cell bank and the production of cell-based ATMP for
clinical applications have to take place in compliance
with the principles of GMP to ensure safety and quality
of the product.
Consequently, the cell isolation, cultivation and cryo-
preservation process were performed according to the
GMP guidelines in the recent study. Sufficient numbers
of cells with acceptable homogenous expression of cellu-
lar marker molecules were obtained, confirming that
adaption from R&D to GMP compliant starting materi-
als was successful. Continuative studies revealed that
cryopreservation influenced cell viability, cellular marker
expression and proliferation potential but without lasting
impact - an important aspect for intended prospective
application as a potential ATMP for cardiovascular tis-
sue engineering. The results of the current study con-
firmed that the application of vascular cells from the
human umbilical cord is in principle possible for estab-
lishing an individual human vascular cell bank under
GMP conditions.
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